| 货号 | AF370-SP |
| 别名 | activin A receptor type II-like 1; activin A receptor, type II-like kinase 1; Activin receptor-like kinase 1; ACVRL1; ACVRLK1ORW2; ALK-1; ALK1TGF-B superfamily receptor type I; EC 2.7.11; HHT; HHT2EC 2.7.11.30; serine/threonine-protein kinase receptor R3; SKR3; TSR-I | 全称 | Activin Receptor-like Kinase 1 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects human ALK-1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 10% cross‑reactivity with recombinant mouse ALK-1 is observed and less than 1% cross-reactivity with recombinant human (rh) Activin RIA and rhActivin RIB is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Immunoprecipitation: David, L. et al. (2007) Blood. 109:1953. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 94 (Human); 11482 (Mouse) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human ALK‑1 Asp22-Gln118 Accession # P37023 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Transforming Growth Factor beta (TGF-beta ) superfamily ligands exert their biological activities via binding to heteromeric receptor complexes of two types (I and II) of serine/threonine kinases. Type II receptors are constitutively active kinases that phosphorylate type I receptors upon ligand binding. In turn, activated type I kinases phosphorylate downstream signaling molecules including the various smads. Transmembrane proteoglycans, including the type III receptor (betaglycan) and endoglin, can bind and present some of the TGF-beta superfamily ligands to type I and II receptor complexes and enhance their cellular responses. Seven type I receptors (also termed activin receptor-like kinase (ALK)) and five type II receptors have been isolated from mammals. ALK-2, -3, -4, -5, and -6 are also known as Activin R1A, BMPR-1A, Activin R1B, TGF-beta R1, and BMPR-1B, respectively, reflecting their ligand preferences. Evidence suggests that TGF-beta 1, TGF-beta 3 and an unknown ligand present in serum can activate chimeric ALK-1. ALK-1 shares with other type I receptors a cysteine-rich domain with conserved cysteine spacing in the extracellular region, and a glycine- and serine-rich domain (the GS domain) preceding the kinase domain. ALK-1 is expressed highly in endothelial cells and other highly vascularized tissues. The expression patterns of ALK-1 parallels that of endoglin. Mutations in ALK-1 as well as in endoglin are associated with hereditary hemorrhagic telangiectasia (HHT), suggesting a critical role for ALK-1 in the control of blood vessel development or repair. Human and mouse ALK-1 share approximately 71% amino acid sequence identity in their extracellular regions. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|